ZA200306159B - N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists. - Google Patents
N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists. Download PDFInfo
- Publication number
- ZA200306159B ZA200306159B ZA200306159A ZA200306159A ZA200306159B ZA 200306159 B ZA200306159 B ZA 200306159B ZA 200306159 A ZA200306159 A ZA 200306159A ZA 200306159 A ZA200306159 A ZA 200306159A ZA 200306159 B ZA200306159 B ZA 200306159B
- Authority
- ZA
- South Africa
- Prior art keywords
- 4alkyl
- 2alkyl
- compound according
- bromo
- fluoro
- Prior art date
Links
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title description 13
- 239000005557 antagonist Substances 0.000 title description 13
- 108010038912 Retinoid X Receptors Proteins 0.000 title description 9
- 102000034527 Retinoid X Receptors Human genes 0.000 title 1
- -1 pyrrolopyrimidinyl Chemical group 0.000 claims description 223
- 125000001424 substituent group Chemical group 0.000 claims description 153
- 150000001875 compounds Chemical class 0.000 claims description 82
- 125000001153 fluoro group Chemical group F* 0.000 claims description 81
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 79
- 125000003118 aryl group Chemical group 0.000 claims description 67
- 150000003839 salts Chemical class 0.000 claims description 62
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 47
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 41
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 37
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 36
- 125000001246 bromo group Chemical group Br* 0.000 claims description 33
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 33
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 208000002193 Pain Diseases 0.000 claims description 13
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 10
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 10
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 9
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 8
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 8
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 8
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 6
- 229910007161 Si(CH3)3 Inorganic materials 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- QUIJMHDIAFOPRK-UHFFFAOYSA-N 1-cyclooctylazocane Chemical group C1CCCCCCC1N1CCCCCCC1 QUIJMHDIAFOPRK-UHFFFAOYSA-N 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 22
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102100040141 Aminopeptidase O Human genes 0.000 claims 1
- 108050008333 Aminopeptidase O Proteins 0.000 claims 1
- 101000608750 Arachis hypogaea Alpha-methyl-mannoside-specific lectin Proteins 0.000 claims 1
- 241000234435 Lilium Species 0.000 claims 1
- 241001602876 Nata Species 0.000 claims 1
- 101000771730 Tropidolaemus wagleri Waglerin-3 Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 26
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108020002076 NR2 subfamily Proteins 0.000 description 4
- 102000038100 NR2 subfamily Human genes 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 3
- 102000034570 NR1 subfamily Human genes 0.000 description 3
- 108020001305 NR1 subfamily Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- NZVZVGPYTICZBZ-UHFFFAOYSA-N 1-benzylpiperidine Chemical group C=1C=CC=CC=1CN1CCCCC1 NZVZVGPYTICZBZ-UHFFFAOYSA-N 0.000 description 1
- UOUIKYFLNQXAFR-UHFFFAOYSA-N 1h-benzimidazole;piperidine Chemical class C1CCNCC1.C1=CC=C2NC=NC2=C1 UOUIKYFLNQXAFR-UHFFFAOYSA-N 0.000 description 1
- CUVGUPIVTLGRGI-UHFFFAOYSA-N 4-(3-phosphonopropyl)piperazine-2-carboxylic acid Chemical compound OC(=O)C1CN(CCCP(O)(O)=O)CCN1 CUVGUPIVTLGRGI-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 description 1
- 102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108091008644 NR2D Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000025609 Urogenital disease Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical class OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 1
- 150000002460 imidazoles Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000002385 psychotomimetic effect Effects 0.000 description 1
- UYLWKSJTHLRFBX-UHFFFAOYSA-N purin-6-one Chemical class O=C1N=CN=C2N=CN=C12 UYLWKSJTHLRFBX-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 108091008646 testicular receptors Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27110001P | 2001-02-23 | 2001-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200306159B true ZA200306159B (en) | 2004-07-05 |
Family
ID=23034191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200306159A ZA200306159B (en) | 2001-02-23 | 2003-08-08 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists. |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7053089B2 (cs) |
| EP (1) | EP1379520B2 (cs) |
| JP (1) | JP4179879B2 (cs) |
| KR (1) | KR100849839B1 (cs) |
| CN (1) | CN100567293C (cs) |
| AT (1) | ATE324371T1 (cs) |
| AU (1) | AU2002252053B2 (cs) |
| BG (1) | BG108113A (cs) |
| BR (1) | BR0207526A (cs) |
| CA (1) | CA2438895A1 (cs) |
| CZ (1) | CZ20032258A3 (cs) |
| DE (1) | DE60210944T3 (cs) |
| DK (1) | DK1379520T3 (cs) |
| EA (1) | EA005974B1 (cs) |
| EC (1) | ECSP034744A (cs) |
| EE (1) | EE200300403A (cs) |
| ES (1) | ES2261658T3 (cs) |
| GE (1) | GEP20063741B (cs) |
| HR (1) | HRP20030669A2 (cs) |
| HU (1) | HUP0303258A3 (cs) |
| IL (2) | IL157254A0 (cs) |
| IS (1) | IS6902A (cs) |
| MX (1) | MXPA03007621A (cs) |
| NO (1) | NO20033732L (cs) |
| NZ (1) | NZ527365A (cs) |
| PL (1) | PL364625A1 (cs) |
| PT (1) | PT1379520E (cs) |
| SI (1) | SI1379520T1 (cs) |
| SK (1) | SK10542003A3 (cs) |
| UA (1) | UA75392C2 (cs) |
| WO (1) | WO2002068409A1 (cs) |
| YU (1) | YU64303A (cs) |
| ZA (1) | ZA200306159B (cs) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2449249A1 (en) * | 2001-06-12 | 2002-12-19 | Merck & Co., Inc. | Nr2b receptor antagonists for the treatment or prevention of migraines |
| US7163952B2 (en) * | 2001-12-03 | 2007-01-16 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7731985B2 (en) * | 2002-03-15 | 2010-06-08 | Ciba Specialty Chemicals Corporation | 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| AU2003231359B2 (en) | 2002-04-16 | 2009-04-30 | Teijin Limited | Piperidine derivatives having CCR3 antagonism |
| WO2003091245A1 (fr) | 2002-04-25 | 2003-11-06 | Teijin Limited | Derives de piperidine 4,4 disubstitues a antagonisme pour ccr3 |
| IL166241A (en) | 2002-07-29 | 2011-12-29 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds for use in the treatment of autoimmune diseases |
| JP2004315511A (ja) * | 2003-03-31 | 2004-11-11 | Taisho Pharmaceut Co Ltd | Ｍｃｈ受容体アンタゴニスト |
| DK1648882T3 (da) * | 2003-06-04 | 2008-11-24 | Merck & Co Inc | 3-fluor-piperidiner som NMDA/NR2B-antagonister |
| US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
| JP4886511B2 (ja) | 2003-07-30 | 2012-02-29 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法 |
| DE602004013806D1 (en) | 2003-09-16 | 2008-06-26 | Astrazeneca Ab | Chinazolinderivate als tyrosinkinaseinhibitoren |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| ES2315834T3 (es) | 2004-02-03 | 2009-04-01 | Astrazeneca Ab | Derivados de quinazolina. |
| CA2567574C (en) | 2004-04-08 | 2013-01-08 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| AU2005271669A1 (en) * | 2004-08-03 | 2006-02-16 | Merck & Co., Inc. | 1,3-disubstituted heteroaryl NMDA/NR2B antagonists |
| WO2006027252A1 (en) * | 2004-09-10 | 2006-03-16 | Ucb Pharma, Sa | Sigma receptor ligands |
| US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| ATE540035T1 (de) | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| MX2007016508A (es) | 2005-06-30 | 2008-03-04 | Prosidion Ltd | Agonistas del receptor acoplado a la proteina g. |
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| BRPI0618179A2 (pt) | 2005-11-01 | 2011-08-23 | Targegen Inc | inibidores de biaril meta pirimidina de cinases |
| EP1966191B1 (en) * | 2005-12-21 | 2010-03-17 | Janssen Pharmaceutica, N.V. | Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| CA2647543A1 (en) * | 2006-03-29 | 2007-11-08 | Foldrx Pharmaceuticals, Inc. | Inhibition of alpha-synuclein toxicity |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| JO2642B1 (en) | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| JP5179509B2 (ja) * | 2006-12-08 | 2013-04-10 | エフ．ホフマン−ラ ロシュ アーゲー | 置換ピリミジン類及びｊｎｋモジュレーターとしてのこれらの使用 |
| MX2009007610A (es) | 2007-02-06 | 2009-07-24 | Boehringer Ingelheim Int | Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion. |
| JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| HRP20120913T1 (hr) * | 2007-04-23 | 2012-12-31 | Janssen Pharmaceutica N.V. | Derivati 4-alkoksipiridazina kao brzo disocirajuä†i antagonisti dopamin 2 receptora |
| KR101506156B1 (ko) * | 2007-04-23 | 2015-03-26 | 얀센 파마슈티카 엔.브이. | 속해리성 도파민 2 수용체 길항제로서의 티아(디아)졸 |
| AU2008290329B2 (en) * | 2007-08-22 | 2011-12-22 | Astrazeneca Ab | Cyclopropyl amide derivatives |
| US20100249164A1 (en) * | 2007-10-31 | 2010-09-30 | Renger John J | Modulation of sleep with nr2b receptor antagonists |
| SI2245026T1 (sl) | 2008-02-07 | 2012-12-31 | Boehringer Ingelheim International Gmbh | Spirociklični heterocikli, zdravila, ki vsebujejo te spojine, njihova uporaba in postopek za njihovo pripravo |
| NZ589883A (en) | 2008-05-13 | 2012-06-29 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline |
| AU2009266001B2 (en) | 2008-07-03 | 2014-03-27 | Janssen Pharmaceutica Nv | Substituted 6- (1-piperazinyl) -pyridazines as 5-HT6 receptor antagonists |
| CN102171189B (zh) | 2008-07-31 | 2013-11-20 | 詹森药业有限公司 | 作为快速解离多巴胺2受体拮抗剂的哌嗪-1-基-三氟甲基取代的吡啶 |
| JP5539351B2 (ja) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法 |
| TW201039825A (en) * | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| US8389536B2 (en) * | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| BR112012020780A2 (pt) * | 2010-02-18 | 2016-05-03 | Astrazeneca Ab | forma sólida, composição farmacêutica, e, uso de uma forma sólida. |
| NZ602110A (en) | 2010-02-18 | 2014-09-26 | Astrazeneca Ab | Processes for making cyclopropyl amide derivatives and intermediates associated therewith |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| JP6001049B2 (ja) * | 2011-03-31 | 2016-10-05 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | Ｍｐｓ−１キナーゼ阻害剤としての置換ベンズイミダゾール類 |
| US8722670B2 (en) * | 2011-09-30 | 2014-05-13 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| ES2627541T3 (es) | 2012-04-20 | 2017-07-28 | Ucb Pharma, S.A. | Métodos para tratar la enfermedad de Parkinson |
| JP2016028017A (ja) * | 2012-12-13 | 2016-02-25 | 大正製薬株式会社 | フッ素置換ピペリジン化合物 |
| JP2017001954A (ja) * | 2013-11-08 | 2017-01-05 | 石原産業株式会社 | 含窒素飽和複素環化合物 |
| JP6500201B2 (ja) * | 2014-05-28 | 2019-04-17 | トーアエイヨー株式会社 | 置換トロパン誘導体 |
| WO2015187845A1 (en) * | 2014-06-04 | 2015-12-10 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists |
| DK3194403T3 (en) * | 2014-09-15 | 2019-04-15 | Rugen Holdings Cayman Ltd | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS |
| WO2016100349A2 (en) * | 2014-12-16 | 2016-06-23 | Rugen Holdings (Cayman) Limited | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists |
| WO2016126869A1 (en) | 2015-02-04 | 2016-08-11 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists |
| EP3872073A1 (en) | 2015-05-11 | 2021-09-01 | Basf Se | Process for preparing 4-amino-pyridazines |
| CN107849010B (zh) | 2015-06-01 | 2021-11-09 | 卢郡控股(开曼)有限公司 | 作为nr2b nmda受体拮抗剂的3,3‐二氟哌啶氨基甲酸酯杂环化合物 |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| MY202227A (en) * | 2018-02-23 | 2024-04-18 | Fraunhofer Ges Zur Frderung Der Angewandten Forschung E V | Novel inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases |
| CN119529020A (zh) * | 2023-11-28 | 2025-02-28 | 成都地奥制药集团有限公司 | 一种含氮杂环化合物、其制备方法及应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL265777A (cs) * | 1960-06-09 | |||
| DE2341965C3 (de) | 1973-08-20 | 1979-01-25 | C.H. Boehringer Sohn, 6507 Ingelheim | 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen |
| US4197304A (en) * | 1975-09-23 | 1980-04-08 | Janssen Pharmaceutica N.V. | N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides |
| WO1984001151A1 (en) * | 1982-09-24 | 1984-03-29 | Beecham Group Plc | Amino-azabicycloalkyl derivatives as dopamine antagonists |
| MX24433A (es) | 1990-02-06 | 1993-05-01 | Pfizer | Derivados de 3-piperidino-1-cromanol y sus analogos y procedimiento para su preparacion |
| AU642994B2 (en) | 1990-05-10 | 1993-11-04 | Pfizer Inc. | Neuroprotective indolone and related derivatives |
| US5189036A (en) | 1990-06-20 | 1993-02-23 | Schering Ag | Imidazolylbenzoyl substituted heterocycles |
| CA2108557A1 (en) | 1991-04-18 | 1992-10-19 | Bertrand L. Chenard | Prodrug esters of phenolic 2-piperidino-1-alkanols |
| HUT70528A (en) | 1991-07-17 | 1995-10-30 | Pfizer | 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents and process for production thereof |
| MY110227A (en) | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| SI9300097B (en) * | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
| DK55192D0 (da) * | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
| US5436255A (en) | 1992-07-23 | 1995-07-25 | Pfizer Inc. | Method of treating diseases susceptable to treatment by blocking NMDA-receptors |
| DE4241632A1 (de) | 1992-12-10 | 1994-06-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| SG63579A1 (en) | 1992-12-21 | 1999-03-30 | Smithkline Beecham Corp | Bicyclic fibrinogen antagonists |
| DE4304650A1 (de) | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| CA2157412A1 (en) | 1993-03-03 | 1994-09-15 | Julia Marie Heerding | Balanoids |
| ATE171447T1 (de) | 1993-03-18 | 1998-10-15 | Merck Sharp & Dohme | Benzimidazole derivate |
| AU3138595A (en) | 1994-07-20 | 1996-02-16 | Acea Pharmaceuticals, Inc. | Haloperidol analogs and the use thereof |
| US5661161A (en) | 1994-09-29 | 1997-08-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP0742208A1 (en) | 1995-05-05 | 1996-11-13 | Grelan Pharmaceutical Co., Ltd. | 2-Ureido-benzamide derivatives |
| JPH11505828A (ja) | 1995-05-26 | 1999-05-25 | ファイザー・インコーポレーテッド | パーキンソン症候群の治療用の選択的ｎｍｄａアンタゴニスト含有組合せ |
| DE69620974T2 (de) | 1995-11-06 | 2003-01-16 | Kuraray Co., Ltd | Verfahren zur Herstellung von Acetalen |
| DE19541264A1 (de) | 1995-11-06 | 1997-05-07 | Bayer Ag | Purin-6-on-derivate |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| ZA9610745B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| FR2744449B1 (fr) | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
| EP0787493A1 (en) | 1996-02-03 | 1997-08-06 | F. Hoffmann-La Roche Ag | Tetrahydroisoquinoline derivatives |
| TW504510B (en) * | 1996-05-10 | 2002-10-01 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives |
| AU2898297A (en) | 1996-05-24 | 1998-01-05 | Novartis Ag | Use of substance p antagonists for treating social phobia |
| SK8199A3 (en) | 1996-07-25 | 2000-04-10 | Biogen Inc | Cell adhesion inhibitors, preparation method thereof and pharmaceutical composition with their content |
| DZ2285A1 (fr) | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Inhibiteurs de protéase de la cystéine. |
| EP0846683B1 (en) | 1996-12-03 | 2001-09-19 | F. Hoffmann-La Roche Ag | 4-Hydroxy-piperidine derivatives |
| FR2758328B1 (fr) | 1997-01-15 | 1999-04-02 | Pf Medicament | Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments |
| FR2758327B1 (fr) | 1997-01-15 | 1999-04-02 | Pf Medicament | Nouvelles arylpiperazines derivees de piperidine |
| IT1291569B1 (it) | 1997-04-15 | 1999-01-11 | Angelini Ricerche Spa | Indazolammidi come agenti serotoninergici |
| US6020347A (en) | 1997-11-18 | 2000-02-01 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
| AU1415099A (en) | 1997-11-18 | 1999-06-07 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
| DE19815026A1 (de) * | 1998-04-03 | 1999-10-07 | Hoechst Schering Agrevo Gmbh | Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
| PE20000728A1 (es) | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
| IL141063A (en) | 1998-08-07 | 2005-06-19 | Applied Research Systems | Derivatives of pyrrolidine-2-carboxylic acid and piperidine-2-carboxylic acids and pharmaceutical compositions comprising said derivatives for treating infertility |
| DE19838300A1 (de) | 1998-08-24 | 2000-03-02 | Bayer Ag | 9-Dialkylaminopurinon-derivate |
| US6303637B1 (en) | 1998-10-30 | 2001-10-16 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
| US7125883B1 (en) | 1999-04-13 | 2006-10-24 | Abbott Gmbh & Co. Kg | Integrin receptor ligands |
| US6329380B1 (en) | 1999-06-30 | 2001-12-11 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
-
2002
- 2002-02-20 CZ CZ20032258A patent/CZ20032258A3/cs unknown
- 2002-02-20 PT PT02721105T patent/PT1379520E/pt unknown
- 2002-02-20 YU YU64303A patent/YU64303A/sh unknown
- 2002-02-20 HR HR20030669A patent/HRP20030669A2/hr not_active Application Discontinuation
- 2002-02-20 AT AT02721105T patent/ATE324371T1/de not_active IP Right Cessation
- 2002-02-20 BR BR0207526-1A patent/BR0207526A/pt not_active IP Right Cessation
- 2002-02-20 EE EEP200300403A patent/EE200300403A/xx unknown
- 2002-02-20 EA EA200300919A patent/EA005974B1/ru not_active IP Right Cessation
- 2002-02-20 JP JP2002567923A patent/JP4179879B2/ja not_active Expired - Fee Related
- 2002-02-20 SK SK1054-2003A patent/SK10542003A3/sk not_active Application Discontinuation
- 2002-02-20 US US10/079,452 patent/US7053089B2/en not_active Expired - Lifetime
- 2002-02-20 HU HU0303258A patent/HUP0303258A3/hu unknown
- 2002-02-20 MX MXPA03007621A patent/MXPA03007621A/es active IP Right Grant
- 2002-02-20 UA UA2003098659A patent/UA75392C2/uk unknown
- 2002-02-20 AU AU2002252053A patent/AU2002252053B2/en not_active Ceased
- 2002-02-20 DE DE60210944.2T patent/DE60210944T3/de not_active Expired - Lifetime
- 2002-02-20 ES ES02721105T patent/ES2261658T3/es not_active Expired - Lifetime
- 2002-02-20 US US10/470,561 patent/US7217716B2/en not_active Expired - Fee Related
- 2002-02-20 PL PL02364625A patent/PL364625A1/xx not_active Application Discontinuation
- 2002-02-20 GE GE5284A patent/GEP20063741B/en unknown
- 2002-02-20 DK DK02721105T patent/DK1379520T3/da active
- 2002-02-20 EP EP02721105.1A patent/EP1379520B2/en not_active Expired - Lifetime
- 2002-02-20 WO PCT/US2002/005226 patent/WO2002068409A1/en active IP Right Grant
- 2002-02-20 CN CNB028087135A patent/CN100567293C/zh not_active Expired - Fee Related
- 2002-02-20 KR KR1020037011079A patent/KR100849839B1/ko not_active Expired - Fee Related
- 2002-02-20 NZ NZ527365A patent/NZ527365A/en unknown
- 2002-02-20 CA CA002438895A patent/CA2438895A1/en not_active Abandoned
- 2002-02-20 SI SI200230322T patent/SI1379520T1/sl unknown
- 2002-02-20 IL IL15725402A patent/IL157254A0/xx active IP Right Grant
-
2003
- 2003-07-31 IS IS6902A patent/IS6902A/is unknown
- 2003-08-05 IL IL157254A patent/IL157254A/en not_active IP Right Cessation
- 2003-08-08 ZA ZA200306159A patent/ZA200306159B/en unknown
- 2003-08-19 BG BG108113A patent/BG108113A/bg unknown
- 2003-08-22 NO NO20033732A patent/NO20033732L/no not_active Application Discontinuation
- 2003-08-22 EC EC2003004744A patent/ECSP034744A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200306159B (en) | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists. | |
| KR20240021884A (ko) | 암을 치료하기 위한 parp 억제제와 조합된 atr 억제제의 용도 | |
| AU771460B2 (en) | Thrombopoietin mimetics | |
| US10144736B2 (en) | Substituted pteridines useful for the treatment and prevention of viral infections | |
| EP0742715B1 (en) | Oral liquid compositions containing paroxetine resinate | |
| ES2267715T3 (es) | Derivados aminados de dihidro-1,3,5-triazina utiles en el tratamiento de patologias asociadas al sindrome de resistencia a la insulina. | |
| HUP0203965A2 (en) | Indazole compounds and pharmaceutical compositions containing them | |
| US20130224151A1 (en) | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | |
| JP2023506787A (ja) | Ｐａｒｐ阻害薬と組み合わせたａｔｒ阻害薬の使用 | |
| RU2008127260A (ru) | Производные хиназолинона в качестве антагонистов ваниллоидов | |
| US20130012589A1 (en) | Stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone | |
| EP2279750A1 (en) | Aniline derivative having anti-rna viral activity | |
| RU2011139157A (ru) | Производное трициклического пиразолопиримидина | |
| EP3653622A1 (en) | Aminopyrimidine compound and composition comprising same and use thereof | |
| WO2017100703A1 (en) | Ems analogues of lyn/src-tyrosine kinase inhibitors | |
| ES2982398T3 (es) | Compuestos novedosos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades renales | |
| EP4101468A1 (en) | Anticancer agent composition | |
| JP2025511732A (ja) | Ａｔｒ阻害薬の使用方法 | |
| WO2017092523A1 (zh) | 一种稠合嘧啶化合物及包含该化合物的组合物及其用途 | |
| CN114853746A (zh) | 甲酰胺类化合物、其制备方法及其在医药上的应用 | |
| HUP0103262A2 (hu) | Platina-komplex vegyületeket tartalmazó gyógyszer valamint alkalmazása | |
| EP3512520B1 (en) | Dithio derivatives of epidithiodiketopiperazine (etp) | |
| US20050101534A1 (en) | Compositions and methods for treating or preventing hearing impairment | |
| WO2020047037A1 (en) | Novel heteroaromatic compounds as potent modulators of the hippo-yap signaling pathway lats1/2 kinases | |
| RU2845210C1 (ru) | Фармацевтическая композиция, включающая ингибитор протеинкиназы и химиотерапевтическое средство, и ее применение |